Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells

Journal of Immunology

Volumn 192, Issue 7, 2014, Pages 3068-3079

  Liu, Guangwei ^a,b   Bi, Yujing ^c   Wang, Ruoning ^d,e   Yang, Hui ^a,b   Zhang, Yan ^a,b   Wang, Xiao ^a,b   Liu, Huanrong ^a,b   Lu, Yun ^a,b   Zhang, Zhengguo ^a,b   Chen, Wanna ^a,b   Chu, Yiwei ^a,b   Yang, Ruifu ^c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b FUDAN UNIVERSITY   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; FINGOLIMOD; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; RAPAMYCIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; IMMUNE MEDIATED INJURY; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER PROTECTION; LYMPHOCYTE DIFFERENTIATION; MORTALITY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TH1 CELL;

ANIMALS; ANTIGENS, CD11B; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG-INDUCED LIVER INJURY; FEMALE; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OMEGA-N-METHYLARGININE; PROPYLENE GLYCOLS; RECEPTORS, CHEMOKINE; RECEPTORS, LYSOSPHINGOLIPID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIROLIMUS; SPHINGOSINE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TOR SERINE-THREONINE KINASES;

EID: 84897557116     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301193     Document Type: Article

References (59)

1. Stan, S. D., S. V. Singh, and R. E. Brand. 2010. Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 7: 347-356.
2. Heneghan, M. A., and I. G. McFarlane. 2002. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7-13.
3. Napoli, J., G. A. Bishop, P. H. McGuinness, D. M. Painter, and G. W. McCaughan. 1996. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24: 759-765.
4. Cacciarelli, T. V., O. M. Martinez, R. G. Gish, J. C. Villanueva, and S. M. Krams. 1996. Immunoregulatory cytokines in chronic hepatitis C virus infection: preand posttreatment with interferon alfa. Hepatology 24: 6-9.
5. Schümann, J., J. Prockl, A. K. Kiemer, A. M. Vollmar, R. Bang, and G. Tiegs. 2003. Silibinin protects mice from T cell-dependent liver injury. J. Hepatol. 39: 333-340.
6. Tiegs, G., J. Hentschel, and A. Wendel. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90: 196-203.
7. Bozza, M., J. L. Bliss, R. Maylor, J. Erickson, L. Donnelly, P. Bouchard, A. J. Dorner, and W. L. Trepicchio. 1999. Interleukin-11 reduces T-celldependent experimental liver injury in mice. Hepatology 30: 1441-1447.
8. Xu, Q., R. Wang, J. Jiang, F. Wu, J. Lu, P. K. Tan, and L. Xu. 1996. Liver injury model in mice induced by a cellular immunologic mechanism-delayed-type hypersensitivity-induced liver injury to picryl chloride and phenotype of effector cell. Cell. Immunol. 167: 38-43.
9. Xu, Q., F. Wu, B. Zhang, J. Jiang, J. Lu, J. Cao, R. Wang, and Z. Feng. 1997. One-shot delayed-type hypersensitivity reaction in the mouse liver causes a sustained liver injury to picryl chloride. Life Sci. 60: 2417-2425.
10. Xu, Q., J. Cao, F. Wu, Y. Hayakawa, I. Saiki, and A. Koda. 1999. Role of Th1 and Th2 cytokines in regulating the liver injury induced by delayed-type hypersensitivity to picryl chloride. Liver 19: 473-480.
11. Tajima, S., N. Nishimura, and K. Ito. 1985. Suppression of delayed-type hypersensitivity mediated by macrophage-like cells in mice with experimental liver injury. Immunology 54: 57-64.
12. Wu, F., J. Cao, J. Jiang, B. Yu, and Q. Xu. 2001. Ruscogenin glycoside (Lm-3) isolated from Liriope muscari improves liver injury by dysfunctioning liverinfiltrating lymphocytes. J. Pharm. Pharmacol. 53: 681-688.
13. Ray, P., M. Arora, S. L. Poe, and A. Ray. 2011. Lung myeloid-derived suppressor cells and regulation of inflammation. Immunol. Res. 50: 153-158.
14. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026.
15. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
16. Jayaraman, P., F. Parikh, E. Lopez-Rivera, Y. Hailemichael, A. Clark, G. Ma, D. Cannan, M. Ramacher, M. Kato, W. W. Overwijk, et al. 2012. Tumorexpressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J. Immunol. 188: 5365-5376.
17. Van Rompaey, N., and A. Le Moine. 2011. Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation. Methods Mol. Biol. 677: 169-180.
18. Choi, J. W., S. E. Gardell, D. R. Herr, R. Rivera, C. W. Lee, K. Noguchi, S. T. Teo, Y. C. Yung, M. Lu, G. Kennedy, and J. Chun. 2011. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 108: 751-756.
19. Shichita, T., Y. Sugiyama, H. Ooboshi, H. Sugimori, R. Nakagawa, I. Takada, T. Iwaki, Y. Okada, M. Iida, D. J. Cua, et al. 2009. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med. 15: 946-950.
20. Brinkmann, V., M. D. Davis, C. E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277: 21453-21457.
21. Brinkmann, V. 2009. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 158: 1173-1182.
22. Kappos, L., E. W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, and P. Burtin; FREEDOMS Study Group. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362: 387-401.
23. Cohen, J. A., F. Barkhof, G. Comi, H. P. Hartung, B. O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, et al; TRANSFORMS Study Group. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362: 402-415.
24. Roberts, E., M. Guerrero, M. Urbano, and H. Rosen. 2013. Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012). Expert Opin. Ther. Pat. 23: 817-841.
25. Ali, R., R. S. Nicholas, and P. A. Muraro. 2013. Drugs in development for relapsing multiple sclerosis. Drugs 73: 625-650.
26. Pham, T. H., T. Okada, M. Matloubian, C. G. Lo, and J. G. Cyster. 2008. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28: 122-133.
27. Schwab, S. R., and J. G. Cyster. 2007. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8: 1295-1301.
28. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
29. Mullershausen, F., F. Zecri, C. Cetin, A. Billich, D. Guerini, and K. Seuwen. 2009. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 5: 428-434.
30. Oo, M. L., S. Thangada, M. T. Wu, C. H. Liu, T. L. Macdonald, K. R. Lynch, C. Y. Lin, and T. Hla. 2007. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282: 9082-9089.
31. Oo, M. L., S. H. Chang, S. Thangada, M. T. Wu, K. Rezaul, V. Blaho, S. I. Hwang, D. K. Han, and T. Hla. 2011. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J. Clin. Invest. 121: 2290-2300.
32. Kaneider, N. C., J. Lindner, C. Feistritzer, D. H. Sturn, B. A. Mosheimer, A. M. Djanani, and C. J. Wiedermann. 2004. The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J. 18: 1309-1311.
33. Liu, G., S. Burns, G. Huang, K. Boyd, R. L. Proia, R. A. Flavell, and H. Chi. 2009. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10: 769-777.
34. Liu, G., K. Yang, S. Burns, S. Shrestha, and H. Chi. 2010. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat. Immunol. 11: 1047-1056.
35. Jiang, J., C. Zhou, and Q. Xu. 2003. Alleviating effects of si-ni-san, a traditional Chinese prescription, on experimental liver injury and its mechanisms. Biol. Pharm. Bull. 26: 1089-1094.
36. Cripps, J. G., J. Wang, A. Maria, I. Blumenthal, and J. D. Gorham. 2010. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 52: 1350-1359.
37. Liu, G., X. Hu, B. Sun, T. Yang, J. Shi, L. Zhang, and Y. Zhao. 2013. Phosphatase Wip1 negatively regulates neutrophil development through p38 MAPKSTAT1. Blood 121: 519-529.
38. Wu, T., C. Sun, Z. Chen, Y. Zhen, J. Peng, Z. Qi, X. Yang, and Y. Zhao. 2012. Smad3-deficient CD11b(+)Gr1(+) myeloid-derived suppressor cells prevent allograft rejection via the nitric oxide pathway. J. Immunol. 189: 4989-5000.
39. Wan, Y. Y., H. Chi, M. Xie, M. D. Schneider, and R. A. Flavell. 2006. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 7: 851-858.
40. Liu, G., Y. Bi, R. Wang, B. Shen, Y. Zhang, H. Yang, X. Wang, H. Liu, Y. Lu, and F. Han. 2013. Kinase AKT1 negatively controls neutrophil recruitment and function in mice. J. Immunol. 191: 2680-2690.
41. Blomgran, R., and J. D. Ernst. 2011. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J. Immunol. 186: 7110-7119.
42. Kaneko, T., T. Murakami, H. Kawana, M. Takahashi, T. Yasue, and E. Kobayashi. 2006. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem. Biophys. Res. Commun. 345: 85-92.
43. Kodumudi, K. N., A. Weber, A. A. Sarnaik, and S. Pilon-Thomas. 2012. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J. Immunol. 189: 5147-5154.
44. Sander, L. E., S. D. Sackett, U. Dierssen, N. Beraza, R. P. Linke, M. Müller, J. M. Blander, F. Tacke, and C. Trautwein. 2010. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207: 1453-1464.
45. Chen, S., S. M. Akbar, M. Abe, Y. Hiasa, and M. Onji. 2011. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin. Exp. Immunol. 166: 134-142.
46. Liang, J., M. Nagahashi, E. Y. Kim, K. B. Harikumar, A. Yamada, W. C. Huang, N. C. Hait, J. C. Allegood, M. M. Price, D. Avni, et al. 2013. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23: 107-120.
47. Brinkmann, V., and K. R. Lynch. 2002. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14: 569-575.
48. Müller, H., S. Hofer, N. Kaneider, H. Neuwirt, B. Mosheimer, G. Mayer, G. Konwalinka, C. Heufler, and M. Tiefenthaler. 2005. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. 35: 533-545.
49. Galicia-Rosas, G., N. Pikor, J. A. Schwartz, O. Rojas, A. Jian, L. Summers- Deluca, M. Ostrowski, B. Nuesslein-Hildesheim, and J. L. Gommerman. 2012. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J. Immunol. 189: 3700-3706.
50. Hla, T., and V. Brinkmann. 2011. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology 76(s8, Suppl. 3) S3-S8.
51. Sawicka, E., G. Dubois, G. Jarai, M. Edwards, M. Thomas, A. Nicholls, R. Albert, C. Newson, V. Brinkmann, and C. Walker. 2005. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J. Immunol. 175: 7973-7980.
52. Daniel, C., N. Sartory, N. Zahn, G. Geisslinger, H. H. Radeke, and J. M. Stein. 2007. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol. 178: 2458-2468.
53. Hegde, V. L., P. S. Nagarkatti, and M. Nagarkatti. 2011. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS ONE 6: e18281.
54. Longhi, M. S., R. R. Mitry, M. Samyn, A. Scalori, M. J. Hussain, A. Quaglia, G. Mieli-Vergani, Y. Ma, and D. Vergani. 2009. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 50: 130-142.
55. Chang, J., P. R. Burkett, C. M. Borges, V. K. Kuchroo, L. A. Turka, and C. H. Chang. 2013. MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc. Natl. Acad. Sci. USA 110: 2270-2275.
56. Chen, C., Y. Liu, Y. Liu, and P. Zheng. 2010. Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. J. Clin. Invest. 120: 4091-4101.
57. Zheng, Y., S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, and J. D. Powell. 2007. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 178: 2163-2170.
58. Memmott, R. M., and P. A. Dennis. 2009. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 21: 656-664.
59. Finlay, D. K., E. Rosenzweig, L. V. Sinclair, C. Feijoo-Carnero, J. L. Hukelmann, J. Rolf, A. A. Panteleyev, K. Okkenhaug, and D. A. Cantrell. 2012. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 209: 2441-2453.